Archives
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2019-05
- 2019-04
- 2018-11
- 2018-10
- 2018-07
-
Introduction The term myeloproliferative disorders was first
2020-07-02

Introduction The term “myeloproliferative disorders” was first proposed by William Dameshek in 1951. With the discovery of the Philadelphia chromosome, myeloproliferative disorders were classified into two groups: BCR-ABL positive chronic myeloid leukemia (CML) and BCR-ABL negative chronic myelopro
-
Herein we report the expression of shrimp
2020-07-02

Herein we report the expression of shrimp Cdk-2 in hepatopancreas, gills and muscle, finding higher expression in hepatopancreas and gills and lower expression in muscle. No significant changes due to hypoxia and hypoxia reoxygenation were detected on the expression of Cdk-2 in hepatopancreas and gi
-
Table shows the clinical data of
2020-07-01

Table 2 shows the clinical data of 23 recipients with CYP3A5*1 allele classified by the presence or absence of CYP3A phenoconversion. Phenoconversion of CYP3A was observed in 10 recipients with CYP3A5*1 allele. No significant differences in eGFR, ALT and total bilirubin were observed between recipie
-
Since we found that the pharmacokinetic properties of
2020-07-01

Since we found that the pharmacokinetic properties of KPT-185 were unsuitable when given subcutaneously or orally, it is not a candidate for in vivo therapy for NHL. However, the pharmacokinetic properties of KPT-276, a CRM1-inhibiting SINE structurally related to and with functional activities simi
-
The inhibition of FAS by C produces an
2020-07-01

The inhibition of FAS by C75 produces an accumulation of malonyl-CoA which is difficult to reconcile with the activation of CPT1 reported by others [2], [16], [17], [18]. To unravel this paradox the mechanism of action of C75 needs to be examined. We recently demonstrated that C75 is converted in vi
-
On the other hand the properties
2020-07-01

On the other hand, the properties of collagen materials could be efficiently improved by proper chemical modification. The crosslinking agents for collagen generally involve aldehydes (e.g., glutaraldehyde (GA), isocyanates (e.g., hexamethylene diisocyanate (HMDI), photoreactive agents, polyepoxy co
-
Ten non FH ADH probands fulfilled the diagnostic
2020-07-01

Ten non-FH ADH probands fulfilled the diagnostic criteria of hyperabsorbers. Table 2 shows the main lipid characteristics of these subjects and of 10 non-hyperabsorber probands used for comparison. There were differences between groups in body mass index, waist circumference and triglycerides. Other
-
br Methods br Discussion and conclusions There
2020-07-01

Methods Discussion and conclusions There were no statistically significant differences in pulmonary function outcomes (FEV1 and FVC) between the placebo and BAY 85-8501 treatment groups. The decline in mean FEV1 from baseline to EOT in the placebo group was attributed statistically to a few pa
-
br Materials and methods br Results
2020-07-01

Materials and methods Results and discussion Conclusions Data about the ability of non-conventional ligands to operate class-A GPCRs have been accumulating. Specifically, increasing evidence indicates that oxysterols, oxidized derivatives of cholesterol, are involved in many activities that
-
We also found downregulation of TRIM in the
2020-07-01

We also found downregulation of TRIM32 in the hearts of dilated and hypertrophic cardiomyopathy patients in addition to TAC and phenylephrine treated mice [51]. TRIM32 and Dysbindin are known to interact in skeletal muscle, and we could confirm this interaction in cardiomyocytes as well. In cardiomy
-
Increased levels of PCNA monoubiquitination by UbL P
2020-07-01

Increased levels of PCNA monoubiquitination by UbL73P expression in a damage-independent manner mimics the phenotype observed for USP1 knockdown (Huang et al., 2006, Jones et al., 2012). USP1 is the only DUB to date shown to remove ubiquitin from PCNA in vivo. This finding reveals the highly dynamic
-
More unusual modifications also regulate DUBs Recent reports
2020-07-01

More unusual modifications also regulate DUBs. Recent reports have illustrated how reactive oxygen species (ROS) can regulate DUB activity 87, 88, 89, 90. ROS can serve as potent signaling molecules by reacting with active site cysteines of tyrosine phosphatases and some cysteine peptidases to form
-
To date many studies have reported
2020-07-01

To date, many studies have reported significant aberrant methylation patterns in TIMPs in various types of cancer Entinostat mg [[16], [17], [18]]. However, little has been reported on the events that lead to the methylation of TIMPs in the UV-irradiated human skin. Therefore, the objective of this
-
Numerous studies have pointed to the DGAT
2020-07-01

Numerous studies have pointed to the DGAT reaction being critical for TAG assembly and in several cases it has been shown to limit carbon flux from lipid precursors towards TAG accumulation [12]. Thus, in Brassica napus, the DGAT substrate, diacylglycerol (DAG), accumulates during periods of rapid l
-
sn-Glycero-3-phosphocholine The most important finding in th
2020-07-01

The most important finding in the present study is that the EKR1/2-Egr-1 signaling pathway might be involve in the mechanisms underlying CysLT2 receptor-mediated IL-8 production. The signaling profile can be described by the following sequential processes: the agonists (LTC4 and LTD4) activates CysL
16471 records 837/1099 page Previous Next First page 上5页 836837838839840 下5页 Last page